VITA News

Viventia Bio, a biotech developing novel antibody drug conjugates for bladder and other cancers, withdrew its plans for an initial public offering on Friday following its acquisition by Eleven Biotherapeutics (EBIO) in September 2016. Eleven paid approximately $13.5 million in newly-issued stock (when its shares traded at $3.37 (now $2.21) plus cash milestones and royalty payments....read more

Viventia Bio, which is developing antibody drug conjugates for bladder and other cancers, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. The Winnipeg, Canada-based company, which was founded in 1995, plans to list on the Nasdaq under the symbol VITA. Viventia Bio filed confidentially on September 17, 2015. Leerink Partners, Cowen...read more